(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release
Posted in Business, Economy, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Carlos Gallardo, Dermatology, Financial, investment
(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release
Posted in Business, Denmark, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Denmark, Dermatology, Dr. Karl Ziegelbauer, IL-21, NN-8828, Novo Nordisk, partnership, sustainability
Nanostructured biomaterial for wound dressings and dermatology to be integrated into Health Care business Evonik Venture Capital’s early investment in 2015 pays off Evonik aims to more than double the share of system solutions in Nutrition & Care by 2030 … Read the full press release
Posted in Business, Chemicals, Germany, Healthcare, Investment, News, Pharma & Biotech, Technology
Tagged acquisition, Bernhard Mohr, biomaterials, bioresorbable polymers, biotech company, biotechnologically derived cellulose, burn treatment, Dana Kralisch, Dermatology, epicite, Evonik, Friedrich-Schiller-University, hydroactive skin care, implantable medical devices, JeNaCell, medical device technologies, medical technology, medical wound dressing, microclimate, pharmaceutical drug products, RESOMER®, surgical wounds, Thomas Riermeier, treatment of chronic wounds, treatment of wounds and burns
(PRESS RELEASE) KORTRIJK, 23-Mar-2021 — /EuropaWire/ — Barco announces partnership with Modernizing Medicine for the interface of its Demetra digital skin imaging system with Modernizing Medicine’s electronic medical record (EMR). The interface aims to create a seamless workflow to reduce … Read the full press release
These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Almirall, AlmirallShare, atopic dermatitis, dermatological conditions, dermatological research, Dermatology, Dublin City University, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, IDIBAPS, inflammatory diseases, Maribel Crespo, medical dermatology, molecular mechanisms, open innovation platform, Prof. Dr. Lluís Puig, Prof. Silvia Vidal, Prof. Tarl Prow, skin cancer, skin carcinoma, skin health, skin immune cell composition, skin transcriptome, skin tumor, Squamous cell Carcinoma, systemic biomarkers, systemic therapy, topical drugs, University College Dublin, University of Namur, University of Sheffield, University of South Australia, University of Turin
Attractive portfolio with strong and successful models of the human skin Global dissemination of regulatory approved alternative test methods Important step towards the worldwide use and distribution of alternative test methods (PRESS RELEASE) DÜSSELDORF, 3-Nov-2020 — /EuropaWire/ — Henkel (ETR: … Read the full press release
The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau (PRESS RELEASE) HANAU, Germany, 4-Oct-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged affordable skin cancer therapy, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, Dermatology, Dr. Holle, epidermal radioisotope therapies, epidermal radioisotope therapy, first Rhenium-SCT treatment Germany, Garching n. Munich, Hanau Rhenium-SCT treatment center, Healthcare, medical device, medicine, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, Pharma & Biotech, physician, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Rehnium-188, Rhenium, Rhenium-188, Rhenium-SCT, science, Shannon D. Brown III, single-session, skin cancer, Squamous cell Carcinoma, Squamous Cell Carcinomas, technology
New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients. (PRESS RELEASE) Pasadena, CA, U.S.A., 5-Jul-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin … Read the full press release
Posted in Awards, Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged affordable skin cancer therapy, Award, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, Dermatology, epidermal radioisotope therapies, epidermal radioisotope therapy, Garching n. Munich, Healthcare, medical device, medicine, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, Pharma & Biotech, physician, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Red Herring Top 100 North America Award, Rehnium-188, Rhenium, Rhenium-188, Rhenium-SCT, science, Shannon D. Brown III, single-session, skin cancer, Squamous cell Carcinoma, Squamous Cell Carcinomas, technology
The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer (PRESS RELEASE) GARCHING N. MUNICH, Germany, 13-May-2019 — /EuropaWire/ — OncoBeta® GmbH, a commercial stage … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged 1st in Germany, affordable skin cancer therapy, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, Dermatology, Dr. med. Lutz-Hendrik Holle, epidermal radioisotope therapies, epidermal radioisotope therapy, Garching n. Munich, Germany, Hanau, Healthcare, medical device, medicine, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, Pharma & Biotech, physician, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Rehnium-188, Rhenium, Rhenium-188, Rhenium-SCT, Rhenium-SCT treatment center, science, Shannon D. Brown III, single-session, skin cancer, Squamous cell Carcinoma, Squamous Cell Carcinomas, technology
LJUBLJANA, Slovenia, 21-Sep-2018 — /EuropaWire/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Slovenia, Technology
Tagged aesthetics, bladder, Chang Gung Memorial Hospital, Chang-Hua Hospital, clinical paper, dentistry, Dermatology, Dr. Adolf Lukanovic, Dr. Mija Blaganje, Dr. Nobuo Okui, Dr. Yi-Hao Lin, Dr. Yi-Wen Tien, dual-tissue regeneration, Dynamis XS, Er:YAG laser therapy, erbium‑doped yttrium aluminum garnet laser therapy, Fotona, Fotona d.o.o., Fotona SMOOTH® Er:YAG laser thermotherapy, Fotona SMOOTH® laser technology, Fotona SMOOTH® technology, genitourinary syndrome of menopause, gynecological treatment options, gynecologists, gynecology, ICIQ-SF, IncontiLase®, IncontiLase® Er:YAG, IncontiLase® Er:YAG laser therapy, International Consultation on Incontinence Questionnaire Short Form, laser irradiation, laser therapy, medical lasers, Non-ablative erbium yttrium aluminum garnet laser, non-invasive treatment of SUI, One-hour pad test, overactive bladder, Overactive bladder symptom score, patient safety, pelvic organ prolapse, premenopausal parous women, ProlapLase®, RenovaLase®, stress, study, SUI, SUI symptoms, superficial heat-shocking mechanism, surgery, surgical sling procedures, Tension-free vaginal tape, tension-free vaginal tape - TVT, thermotherapy, tissue regeneration, TOT procedures, Transobturator tape, transobturator tape - TOT, TVT procedures, urinary incontinence, urodynamic stress incontinence, vaginal collagen hyperthermia, vaginal laxity – vaginal relaxation syndrome, vaginal tissues, vaginal wall, World Journal of Urology
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab … Read the full press release
Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?